

Ophthalmology APIs


The natural compound prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$) activates signaling pathways in the eye that reduce intraocular pressure (IOP). A family of $PGF_{2\alpha}$ analogs, including bimatoprost, latanoprost, tafluprost, and travoprost, have been developed, and these compounds are more potent than $PGF_{2\alpha}$ itself in lowering IOP and have fewer side effects. Moreover, they are known to be safe and effective when used in the treatment of glaucoma.

- US FDA and EMA compliant
- Analytical standards of impurities and degradation products available



Commercial API Production


CGMP Latanoprost



CAS Number 130209-82-4

Availability GMP material from both Cayman Chemical and Cayman Pharma, which conforms to the USP, EP, and IP Monographs, is available. Each site maintains a unique DMF; they have been filed with the US FDA, Canada, India, several EU member states, and several other countries. Cayman Chemical GMP material has been granted a Certificate of Suitability (CEP) as of 28 August 2023.


CGMP Latanoprostene Bunod



CAS Number 860005-21-6

Availability GMP material is available, and the DMF for Latanoprostene Bunod is available for customer review upon request. The DMF has been filed with the US FDA.


CGMP Tafluprost



CAS Number 209860-87-7

Availability GMP material is available, and the DMF for Tafluprost is available for customer review upon request. The DMF has been filed with the US FDA.


CGMP Bimatoprost



CAS Number 155206-00-1

Availability GMP material is available, and the DMF for Bimatoprost is on file with the US FDA, Canada, Brazil, and India.

CGMP Travoprost



CAS Number 157283-68-6

Availability GMP material, which conforms to the USP Monograph, is available. The DMF is on file with the US FDA, Canada, India, Japan, China, several EU member states, and several other countries.